The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting
Abstract
Background: Obesity is a chronic disease with rising prevalence. Guidelines suggest medications for obesity management if lifestyle interventions do not lead to substantial weight loss. Randomized control trials have shown the efficacy of anti-obesity medications in inducing weight loss, but real-world data are lacking. Therefore, our study aims to evaluate anti-obesity medications’ effectiveness in reducing weight and improving cardiometabolic parameters and to assess their persistence in a real-world setting. Methods: A historical cohort study using routinely collected data from Clalit Health Services (CHS). We retrieved data on all CHS members aged ≥20 years who initiated anti-obesity medication (orlistat, liraglutide 3 mg, and lorcaserin) between 2018 and 2020. We assessed average weight loss and the percentage of patients that had lost ≥5% and ≥10% of their body weight at 3, 6, and 9 months and compared the effectiveness of these 3 medications. Results: We included 5,306 CHS members in our study; most (77.8%) were female, aged 40–59 years (52.4%). Treatment with liraglutide 3 mg and lorcaserin was associated with subsequent weight reduction. The average weight loss at 6 months was 5.6 kg (4.95–6.25, 95% confidence interval [CI]) with liraglutide 3 mg and 1.7 kg (1.2–2.2, 95% CI) with lorcaserin. There was no evidence that treatment with orlistat was associated with subsequent weight loss (−0.18 kg [−0.8 to 0.4, 95% CI]). At 6 months, 38% of the patients with orlistat, 43% with lorcaserin, and 51% with liraglutide 3 mg persisted with their treatments (P < 0.001). Conclusion: Liraglutide 3 mg was the primary medication associated with clinically significant weight loss and had the highest persistence rate in our real-world study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We found insufficient data from observational comparative effectiveness research designs to understand the real world treatment effectiveness and safety of antiobesity medications.”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [80]
In the citing paper
“The majority of RWS conducted in patients initiating incretin-based AOM were retrospective51–71 and included liraglutide users, while only a few studies investigated semaglutide titrated up to 2.4 mg65,66,69–71 (Tables 1 and 2).”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [52]
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Caregiving for Older Adults with Obesity in the United States
Ankuda, C. K., Harris, J., Ornstein, K., Levine, D. A., Langa, K. M., & Kelley, A. S. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14918 · Cited by 1,684
Long-term weight-loss maintenance: a meta-analysis of US studies
Anderson, J. W., Konz, E. C., Frederich, R. C., & Wood, C. L. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.5.579 · Cited by 1,351
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care
Durrer Schutz, D., Busetto, L., Dicker, D., Farpour-Lambert, N., Pryke, R., Toplak, H., Widmer, D., Yumuk, V., & Schutz, Y. (2019) · Obesity Facts · doi:10.1159/000496183 · Cited by 492
Steele, C. B., Thomas, C. C., Henley, S. J., Massetti, G. M., Galuska, D. A., Agurs-Collins, T., Puckett, M., & Richardson, L. C. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6639e1 · Cited by 408
Eichler, H.-G., Abadie, E., Breckenridge, A., Flamion, B., Gustafsson, L. L., Leufkens, H., Rowland, M., Schneider, C. K., & Bloechl-Daum, B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3501 · Cited by 369
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265
Nallamothu, B. K., Hayward, R. A., & Bates, E. R. (2008) · Circulation · doi:10.1161/circulationaha.107.703579 · Cited by 250
Cefalu, W. T., Bray, G. A., Home, P. D., Garvey, W. T., Klein, S., Pi-Sunyer, F. X., Hu, F. B., Raz, I., Van Gaal, L., Wolfe, B. M., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1081 · Cited by 243
Health and health care in Israel: an introduction
Clarfield, A. M., Manor, O., Nun, G. B., Shvarts, S., Azzam, Z. S., Afek, A., Basis, F., & Israeli, A. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30636-0 · Cited by 214
Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2003873 · Cited by 147
Sahebkar, A., Simental‐Mendía, L. E., Reiner, Ž., Kovanen, P. T., Simental-Mendía, M. A., Bianconi, V., & Pirro, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.022 · Cited by 127
Long‐term weight loss effects on all cause mortality in overweight/obese populations
Poobalan, A. S., Aucott, L. S., Smith, W. C. S., Avenell, A., Jung, R. T., & Broom, J. I. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00393.x · Cited by 95
Suliman, M., Buckley, A., Al Tikriti, A., Tan, T., le Roux, C. W., Lessan, N., & Barakat, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13672 · Cited by 86
Gorgojo‐Martínez, J. J., Basagoiti‐Carreño, B., Sanz‐Velasco, A., Serrano‐Moreno, C., & Almodóvar‐Ruiz, F. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13399 · Cited by 82
Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
Wharton, S., Liu, A., Pakseresht, A., Nørtoft, E., Haase, C. L., Mancini, J., Power, G. S., Vanderlelie, S., & Christensen, R. A. G. (2019) · Obesity · doi:10.1002/oby.22462 · Cited by 77
Ahmad, N. N., Robinson, S., Kennedy‐Martin, T., Poon, J. L., & Kan, H. (2021) · Obesity Reviews · doi:10.1111/obr.13326 · Cited by 69
Persistence of newer anti-obesity medications in a real-world setting
Ganguly, R., Tian, Y., Kong, S. X., Hersloev, M., Hobbs, T., Smolarz, B. G., Ramasamy, A., Haase, C. L., & Weng, W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.017 · Cited by 68
Calderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-021-01019-6 · Cited by 52
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U. (2021) · Obesity Facts · doi:10.1159/000518325 · Cited by 41
Douglas, I., Bhaskaran, K., Batterham, R. L., & Smeeth, L. L. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12578 · Cited by 34
Sahebkar, A., Simental‐Mendía, L. E., Kovanen, P. T., Pedone, C., Simental-Mendía, M. A., & Cicero, A. F. G. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.12.002 · Cited by 33
Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center
Ferrari, F., Fierabracci, P., Salvetti, G., Jaccheri, R., Vitti, J., Scartabelli, G., Meola, A., Magno, S., Ceccarini, G., & Santini, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01334-1 · Cited by 29
The Benefit of Short-Term Weight Loss with Anti-Obesity Medications in Real-World Clinical Practice
Shibuya, K., Ali, K. F., Ji, X., Milinoivh, A., Bauman, J., Kattan, M. W., Pantalone, K. M., & Burguera, B. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0081 · Cited by 27
A review and critique of published real-world weight management program studies
Primack, C. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1498280 · Cited by 13
Beyond lifestyle interventions: exploring the potential of anti‐obesity medications in the UK
Wilding, J. P. H. (2018) · Clinical Obesity · doi:10.1111/cob.12248 · Cited by 13
Research works printed but not linked: 1
- Ogden, 2015, Prevalence of obesity among adults and youth: United States, 2011–2014, NCHS Data Brief, 219, 1
Cited by
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Patoulias, D., Koufakis, T., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s471476 · Cited by 19
Dobbie, L. J., Coelho, C., Mgaieth, F., Chauhan, K., Campbell, S., Shuriye, S., Hollington, J., Appleton, S., Sen Gupta, P., Duncan, A., et al. (2024) · Clinical Obesity · doi:10.1111/cob.12649 · Cited by 12
Basolo, A., Paolucci, G., Piaggi, P., Angeli, V., Genzano, S. B., Fierabracci, P., Vignali, E., Bologna, C., Salvetti, G., Chiovato, L., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02717-y · Cited by 10
Metadata
- Authors
- Leventhal-Perek, S., Shani, M., & Schonmann, Y.
- Affiliations
- Tel Aviv University (IL)
- Ben-Gurion University of the Negev (IL)
- Corresponding author
- Leventhal-Perek, Sharon
- Venue
- Family Practice
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-12-08
- Volume
- 40
- Issue
- 5-6
- Pages
- 629-637
- ISSN
- 0263-2136 (ISSN-L)
- 1460-2229
- OpenAlex
- W4310960180
- Cited by
- 11
- References
- 36
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Family Practice (publishedVersion)
- PubMed (publishedVersion)
- Funders
- departmental resources
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, obesity, weight loss, lorcaserin, orlistat, treatment persistence, cardiometabolic parameters, primary care, real-world effectiveness
- MeSH terms
- Liraglutide, Orlistat, Benzazepines, Female, Humans, Male, Primary Health Care, Cohort Studies, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.